Interactions between galantamine and Accolate (zafirlukast)
zafirlukast and galantamine (Moderate Drug-Drug)
MANAGEMENT: Pharmacologic response to galantamine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the galantamine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience excessive cholinergic symptoms such as severe nausea, vomiting, GI cramping, salivation, lacrimation, sweating, dizziness, or syncope.






